PolyPid (NASDAQ:PYPD) Trading 4.8% Higher

PolyPid Ltd. (NASDAQ:PYPD – Get Rating) traded up 4.8% during trading on Wednesday . The stock traded as high as $0.39 and last traded at $0.37. 94,833 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 288,958 shares. The stock had previously closed at $0.35.

PolyPid Price Performance

The stock has a market cap of $7.18 million, a P/E ratio of -0.22 and a beta of 1.25. The company has a current ratio of 2.75, a quick ratio of 2.75 and a debt-to-equity ratio of 0.59. The company has a 50 day simple moving average of $0.42 and a 200 day simple moving average of $0.64.

PolyPid (NASDAQ:PYPD – Get Rating) last announced its quarterly earnings data on Wednesday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter. Sell-side analysts forecast that PolyPid Ltd. will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PolyPid

A number of institutional investors and hedge funds have recently made changes to their positions in PYPD. Boothbay Fund Management LLC raised its stake in shares of PolyPid by 514.5% during the 1st quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock worth $57,000 after purchasing an additional 102,898 shares in the last quarter. UBS Group AG raised its stake in shares of PolyPid by 29.9% during the 1st quarter. UBS Group AG now owns 285,399 shares of the company’s stock worth $1,558,000 after purchasing an additional 65,746 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of PolyPid by 83.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock worth $285,000 after acquiring an additional 23,752 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of PolyPid during the 1st quarter worth approximately $72,000. Finally, Silverarc Capital Management LLC increased its holdings in shares of PolyPid by 1.2% during the 1st quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock worth $1,191,000 after acquiring an additional 2,555 shares during the last quarter. Institutional investors own 2.48% of the company’s stock.

PolyPid Company Profile

(Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.